Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019046378) H3K27 DEMETHYLASE INHIBITORS IN PEDIATRIC AND JUVENILE OSTEOPOROSIS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/046378 International Application No.: PCT/US2018/048465
Publication Date: 07.03.2019 International Filing Date: 29.08.2018
IPC:
A61K 31/55 (2006.01) ,A61P 19/10 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
55
having seven-membered rings, e.g. azelastine, pentylenetetrazole
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
19
Drugs for skeletal disorders
08
for bone diseases, e.g. rachitism, Paget's disease
10
for osteoporosis
Applicants:
THE JOHNS HOPKINS UNIVERSITY [US/US]; 3400 N. Charles Street Baltimore, Maryland 21218, US
Inventors:
WAN, Mei; US
CAO, Xu; US
Agent:
CONTRERA, Joseph; US
Priority Data:
62/553,30801.09.2017US
Title (EN) H3K27 DEMETHYLASE INHIBITORS IN PEDIATRIC AND JUVENILE OSTEOPOROSIS
(FR) INHIBITEURS DE H3K27 DÉMÉTHYLASE DANS L'OSTÉOPOROSE PÉDIATRIQUE ET JUVÉNILE
Abstract:
(EN) The present invention provides methods for manipulating epigenetic factors to treat pediatric or juvenile osteoporosis. Specifically, the present invention provides methods for the application of H3K27 demethylase inhibitors in pediatric or juvenile subjects with osteoporosis. Thus, the present invention provides methods of administration of the H3K27 demethylase inhibitor, GSK-J4, to pediatric or juvenile subjects to effectively inhibit primary and secondary pediatric osteoporosis, especially for long-term glucocorticoid treated patients (juvenile rheumatoid disorders, Crohn's disease, nephrotic syndrome, and Duchenne muscular dystrophy) and patients who have compromised mobility (cerebral palsy, Rett syndrome, Duchenne muscular dystrophy, spina bifida, and spinal muscular atrophy).
(FR) La présente invention concerne des procédés de manipulation de facteurs épigénétiques pour traiter l'ostéoporose pédiatrique ou juvénile. Spécifiquement, la présente invention concerne des procédés pour l'application d'inhibiteurs de la H3K27 déméthylase chez des sujets pédiatriques ou jeunes atteint d'ostéoporose. Ainsi, la présente invention concerne des procédés d'administration de l'inhibiteur de la H3K27 déméthylase, GSK-J4, à des sujets pédiatriques ou jeunes pour inhiber efficacement l'ostéoporose pédiatrique primaire et secondaire, en particulier pour des patients traités par des glucocorticoïdes à long terme (troubles rhumatoïdes juvénile, maladie de Crohn, syndrome néphrotique et dystrophie musculaire de Duchenne) et les patients qui ont une mobilité compromise (infirmité motrice cérébrale, syndrome de Rett, dystrophie musculaire de Duchenne, spina bifida, et atrophie musculaire spinale).
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)